Last updated: February 27, 2026
What Is NDC 13668-0569?
The National Drug Code (NDC) 13668-0569 refers to Praxbind (idarucizumab). It is a monoclonal antibody designed as a reversal agent for the anticoagulant dabigatran (Pradaxa). Approved by the FDA in October 2015, Praxbind is used primarily in emergency settings to counteract serious bleeding or the need for urgent surgery in patients on dabigatran.
Market Overview
Therapeutic Context and Revenue Drivers
- Indication: Reversal of anticoagulation in dabigatran-treated patients.
- Market Size: As of 2023, approximately 2.34 million Americans are on dabigatran, with usage expected growth driven by increased anticoagulation therapy approvals.
- Reversal Agent Market: Praxbind competes primarily with Andexanet alfa (for factor Xa inhibitors, e.g., rivaroxaban, apixaban). The reversal market for anticoagulants is projected at $1.2 billion globally in 2023, with Praxbind projected to capture roughly 15-25% of secondary reversal agent use.
Market Penetration and Usage Trends
- Hospital Adoption: Praxbind availability at roughly 60% of US hospitals equipped for emergency anticoagulation reversal.
- Usage Rates: Estimated that 10-15% of dabigatran-treated patients experience clinical scenarios requiring reversal annually.
- Competitive Landscape: As of 2023, Praxbind remains the sole FDA-approved specific reversal agent for dabigatran, with off-label use and institutional protocols influencing market share.
Prescriber and Institutional Dynamics
- Emergency departments and hospitals with higher anticoagulation case volumes are the primary prescribers.
- Insurance reimbursements and hospital formulary decisions influence adoption.
- Awareness campaigns and updated clinical guidelines support increased usage.
Price Analysis and Projection
Current Pricing Structure
- List Price per 2 g vial: Approximately USD 4,600.
- Average Reimbursement Rate: ~$3,850 per vial (varies by payer and region).
- Typical Dosing: Two 2.5 g vials per reversal event; total cost approximately USD 9,200.
Factors Influencing Price Trends
- Market Competition: Limited direct competitors; however, off-label use and alternative reversal strategies (e.g., high-dose administration of PCCs) influence pricing.
- Manufacturing Costs: Production costs associated with monoclonal antibodies remain high; expected slight decreases due to manufacturing process optimizations.
- Clinical Guidelines and Usage: More conservative adoption may pressure pricing downward if demand stabilizes; increased adoption could sustain or slightly increase price levels.
Price Projections (2023-2028)
| Year |
Estimated Price per 2 g Vial |
Comments |
| 2023 |
USD 4,600 |
Stabilized due to limited competition. |
| 2024 |
USD 4,500 |
Slight decline expected due to market maturation. |
| 2025 |
USD 4,400 |
Continued downward pressure, influenced by healthcare cost containment. |
| 2026 |
USD 4,300 |
Margin compression expected as payer negotiations intensify. |
| 2027 |
USD 4,200 |
Potential for further reductions if new therapies or generic biosimilars emerge. |
| 2028 |
USD 4,100 |
Establishing a new baseline, barring significant biotech breakthroughs. |
Revenue Projections
Assuming market penetration remains steady:
- 2023 Revenue: USD 240 million (assuming 52,200 dose events annually).
- 2025 Revenue: USD 210 million.
- 2028 Revenue: USD 180 million.
Regulatory and Reimbursement Factors
- Continued approval and inclusion in clinical guidelines support stable demand.
- Reimbursement policies will influence real-world prices and hospital use.
- Patent protections or market exclusivities are expected to last until 2030, securing pricing power.
Key Takeaways
- Praxbind (NDC 13668-0569) is the primary reversal agent for dabigatran, with a stable market due to lack of direct competitors.
- Pricing is approximately USD 4,600 per vial, with modest downward pressure projected.
- Market growth hinges on increasing dabigatran use, hospital adoption, and clinical guideline updates.
- Revenues are expected to decline gradually through 2028 due to market maturation and payer negotiations.
Frequently Asked Questions
Q1: What factors could accelerate Praxbind’s price decline?
Introduction of competing reversal agents, generic biosimilars, or alternative reversal strategies could lower prices.
Q2: How does Praxbind compare with alternatives like Andexanet alfa?
Praxbind specifically targets dabigatran, while Andexanet alfa reverses factor Xa inhibitors. Cost, efficacy, and safety profiles influence prescriber preference.
Q3: What is the impact of clinical guidelines on Praxbind's utilization?
Guidelines endorsing timely reversal can lead to increased use, stabilizing or raising prices if demand surges.
Q4: Are there upcoming patent expirations affecting pricing?
Patent protections extend until approximately 2030; biosimilar development could influence future pricing.
Q5: How does hospital adoption impact revenue projections?
Higher adoption rates in hospitals directly correlate with increased usage and revenue, especially in emergency settings.
References
[1] FDA (2015). "FDA approves Praxbind to reverse effects of Pradaxa." U.S. Food and Drug Administration.
[2] EvaluatePharma (2023). "Global anticoagulation reversal therapeutics market."
[3] IQVIA (2023). "Hospital prescribing data on reversal agents."
[4] MarketWatch (2023). "Drug pricing trends for monoclonal antibody products."
[5] Centers for Medicare & Medicaid Services (CMS). "Reimbursement policies for hospital drugs."
